NCT06135922View on ClinicalTrials.gov

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
EBV-associated Hemophagocytic LymphohistiocytosisEBV Infection
Interventions
BIOLOGICAL

EBV-TCR-T cells

The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER